{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-017285","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2025-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.405651+00:00","generated_at":"2026-05-18T10:33:05.312620+00:00","sec_items":["1.01","3.02","3.03","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biofrontera acquires U.S. rights to Ameluz/RhodoLED from Biofrontera AG; raises $11M via Series C preferred","bullets":["Acquired all U.S. rights to Ameluz and RhodoLED from Biofrontera AG; will pay royalty of 12% or 15% based on $65M revenue threshold.","Biofrontera AG receives 3,109 Series D Convertible Preferred shares (10% post-money equity stake) as part of consideration.","Private placement of up to 11,000 Series C Preferred shares at $1,000 each for gross proceeds of up to $11.0M to fund the deal.","Initial closing of $8.5M expected July 1, 2025; subsequent closing of $2.5M expected by September 30, 2025.","Conversion and voting rights of both preferred series are subject to stockholder approval under Nasdaq rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-017285","json":"https://secwatch.observer/filing/0001641172-25-017285.json","markdown":"https://secwatch.observer/filing/0001641172-25-017285.md","text":"https://secwatch.observer/filing/0001641172-25-017285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000164117225017285/0001641172-25-017285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000164117225017285/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T10:33:05.312620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}